Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00396_DB01030_nanopub.RAvlW2nodWt4wg3teWnRrZVYrj2pBgSgec7QX5s1hm8Pw#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00396_DB01030 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00396_DB01030 label "DDI between Progesterone and Topotecan - The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. [drugbank_resource:DB00396_DB01030]" assertion.
- drugbank_resource:DB00396_DB01030 identifier "drugbank_resource:DB00396_DB01030" assertion.
- drugbank_resource:DB00396_DB01030 title "DDI between Progesterone and Topotecan - The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided." assertion.
- drugbank:DB01030 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00396_DB01030 assertion.
- drugbank:DB00396 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00396_DB01030 assertion.